BE498589A - - Google Patents
Info
- Publication number
- BE498589A BE498589A BE498589DA BE498589A BE 498589 A BE498589 A BE 498589A BE 498589D A BE498589D A BE 498589DA BE 498589 A BE498589 A BE 498589A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- chloramphenicol
- solution
- water
- amide
- Prior art date
Links
- 229960005091 chloramphenicol Drugs 0.000 claims description 35
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 35
- 150000001408 amides Chemical class 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 16
- 230000003287 optical effect Effects 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- -1 dichloroacetamido Chemical group 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000004575 stone Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229940113088 dimethylacetamide Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 150000003511 tertiary amides Chemical class 0.000 description 3
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 201000009482 yaws Diseases 0.000 description 2
- 240000000254 Agrostemma githago Species 0.000 description 1
- 235000009899 Agrostemma githago Nutrition 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical group CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000531819 Streptomyces venezuelae Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 238000002642 intravenous therapy Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003334 secondary amides Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE498589A true BE498589A (en)van) |
Family
ID=141219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE498589D BE498589A (en)van) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE498589A (en)van) |
-
0
- BE BE498589D patent/BE498589A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2102777C (fr) | Nouvelles compositions a base de derives de la classe des taxanes | |
| EP0671912B1 (fr) | Compositions injectables a base de derives des taxanes | |
| JPH057371B2 (en)van) | ||
| BE897761A (fr) | Nouvelles compositions pharmaceutiques a base de cis-platine et procede pour les preparer | |
| JPH0326183B2 (en)van) | ||
| BE1003647A5 (fr) | Composition pharmaceutique de nicardipine pour administration parenterale. | |
| CN101541324B (zh) | 医药组合物 | |
| LU86484A1 (fr) | Sels de furosemide | |
| BE498589A (en)van) | ||
| FR2505834A1 (fr) | Derives de la thiazolidine | |
| HU177873B (en) | Further developped process for preparing an aequous solution containing a complex of n-/3-chloro-4-/4-chloro-phenoxy/-phenyl/-2-hydroxy-3,5-diiodo-benzamide with polyvinyl-pyrrolidone | |
| FR2532309A1 (fr) | Perfluorocycloamines et preparation d'emulsions therapeutiques contenant ces perfluorocycloamines | |
| BE897580A (fr) | Nouveaux derives de la benzamide leur preparation et les compositions pharmaceutiques qui les contiennent | |
| BE1001704A3 (fr) | Compositions aqueuses contenant un derive de l'acide piperidinylcyclopentylheptenoique. | |
| LU85812A1 (fr) | Forme dosee d'etoposide a usage oral | |
| JPH0144172B2 (en)van) | ||
| CH641775A5 (fr) | N-(1-methyl 2-pyrrolidinyl methyl) 2,3-dimethoxy 5-methylsulfamoyl benzamide et ses derives, son procede de preparation et composition le renferment. | |
| LU84346A1 (fr) | Nouveau sel de n-methyl-d-glucamine et medicament le contenant | |
| CH291374A (fr) | Procédé de préparation d'une composition thérapeutique stable et limpide, à action antibiotique. | |
| CH645901A5 (fr) | Sel sesqui-sodique d'un diacide d'oxa-beta-lactame antibiotique. | |
| JP2000072673A (ja) | 塩酸ニカルジピン含有液剤 | |
| CH622023A5 (en) | Process for the preparation of a water-soluble compound based on a substituted phenylaminoalcohol | |
| FR2461498A1 (fr) | Procede de preparation de solutions concentrees d'amygdaline sous sa forme naturelle, et produits ainsi obtenus | |
| LU83081A1 (fr) | Compositions antitumeurs | |
| BE556150A (en)van) |